Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 1;274(6):e690-e691.
doi: 10.1097/SLA.0000000000003860.

Response to the Comment on "Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer"

Yoshinaga Okugawa  1   2 , Yuji Toiyama  1 , Masaki Ohi  1 , Masato Kusunoki  1
Affiliations
Comment

Response to the Comment on "Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer"

Yoshinaga Okugawa et al. Ann Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Comment on

References

    1. Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg 2019; 10.1097/SLA.0000000000003239. - DOI
    1. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373–1379.
    1. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48:1503–1510.
    1. Okugawa Y, Toiyama Y, Fujikawa H, et al. Prognostic potential of lymphocyte–C-reactive protein ratio in patients with rectal cancer receiving preoperative chemoradiotherapy. J Gastrointest Surg 2020; doi.org/10.1007/s11605-019-04495-4. - DOI
    1. Andre T, Vernerey D, Mineur L, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III Colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, phase III trial. J Clin Oncol 2018; 36:1469–1477.